Hybridoma cell line G250 and its use for producing monoclonal antibodies

Abstract

This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G 250 . Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G 250 as well as derivatives thereof such as chimeric and humanized G 250 antibodies.

1 . Hybridoma cell DSM ACC 2526 which produces the monoclonal antibody G250. 
     
     
         2 . Cell derived from hybridoma cell DSM ACC 2526 which produces a G250 antibody. 
     
     
         3 . The cell according to  claim 2  which has been obtained by transfer of genetic material encoding antibody G250 or at least the antigen-binding site thereof into a receptor cell. 
     
     
         4 . The cell according to  claim 2  which produces a chimeric antibody, a humanized antibody, a fully humanized antibody, a bispecific antibody, a single chain antibody, or F(ab′) 2 , Fab′, or Fab antibody fragments. 
     
     
         5 . The receptor cell according to  claim 3  which is a prokaryotic cell. 
     
     
         6 . The cell according to  claim 5  which is an  E. coli  cell. 
     
     
         7 . The cell of  claim 3  which is a eukaryotic cell. 
     
     
         8 . The cell according to  claim 7  which is a yeast cell, a myeloma cell or a CHO-cell. 
     
     
         9 . A method of producing a G250 antibody comprising:
 cultivating a cell according to  claim 1  under suitable conditions, wherein the antibody is produced and obtaining the antibody from the cell and/or from the culture medium.   
     
     
         10 . The method according to  claim 8  used for producing a pharmaceutical formulation which comprises the G250 antibody as an active agent. 
     
     
         11 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody. 
     
     
         12 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody in radiolabeled form. 
     
     
         13 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises a chimeric G250 antibody coupled to a cytokine such as IL-2, TNF and/or GM-CSF. 
     
     
         14 . Use of a cell according to  claim 1  for the manufacture of a G250 antibody. 
     
     
         15 . Use of a G250 antibody for the manufacture of an agent for eliciting a delayed immune response in cancer therapy. 
     
     
         16 . The use of  claim 15  in the treatment of renal cell carcinoma. 
     
     
         17 . The use of  claim 15  for the treatment of metastases after tumor surgery.